Studies in methamphetamine (METH) abusers showed that the decreases in brain dopamine (DA) function might recover with protracted detoxification. However, the extent to which striatal DA function in METH predicts recovery has not been evaluated. Here we assessed whether striatal DA activity in METH abusers is associated with clinical outcomes. Brain DA D2 receptor (D2R) availability was measured with positron emission tomography and [ 11 C]raclopride in 16 METH abusers, both after placebo and after challenge with 60 mg oral methylphenidate (MPH) (to measure DA release) to assess whether it predicted clinical outcomes. For this purpose, METH abusers were tested within 6 months of last METH use and then followed up for 9 months of abstinence. In parallel, 15 healthy controls were tested. METH abusers had lower D2R availability in caudate than in controls. Both METH abusers and controls showed decreased striatal D2R availability after MPH and these decreases were smaller in METH than in controls in left putamen. The six METH abusers who relapsed during the follow-up period had lower D2R availability in dorsal striatum than in controls, and had no D2R changes after MPH challenge. The 10 METH abusers who completed detoxification did not differ from controls neither in striatal D2R availability nor in MPH-induced striatal DA changes. These results provide preliminary evidence that low striatal DA function in METH abusers is associated with a greater likelihood of relapse during treatment. Detection of the extent of DA dysfunction may be helpful in predicting therapeutic outcomes.
Introduction
Several preclinical studies have been reported on the deleterious effects of methamphetamine (METH) to dopamine (DA) cells. These studies have shown that METH can produce long-lasting changes on DA cell markers, 1, 2 including decreases in brain DA content, tyrosine hydroxylase activity, DA uptake and DA transporter (DAT) levels. 3, 4 METH-induced changes in these DA markers have been associated with motor and learning deficits in rodents, indicating that they are functionally significant. 5, 6 These DA effects have been interpreted as evidence of neurotoxicity, which is corroborated by studies that show METH induced DA nerve terminal degeneration and reactive gliosis in striatum. 7, 8 More recent human imaging studies revealed correlation of memory deficits and decrement of DAT binding potential, 9 as well as reduced striatal DA D2 receptor (D2R) and impulsivity in METH abusers. 10 Though it is generally believed that the effects of METH are limited to the terminals while sparing the soma, DA cell death has also been reported. 11 Non-human primate studies report that the DA changes induced by METH are long lasting and present at least 6 months after drug administration. 12 However, more recent work has documented significant recovery from METH-induced DA terminal changes. Studies investigating the recovery of DA brain neurotransmission after METH have shown results that vary from complete recovery to persistent long-lasting changes. In rats, a marked reduction in baseline DA levels and amphetamine-induced increases in DA release were observed 1 week after METH administration, with recovery to normal values 12 months after treatment. 13 Significant, though not complete, recovery in DA function after METH administration was reported in a rodent study that showed marked depletions in DA (30% of controls) 1 week after METH that recovered 7 months after treatment (80% of controls). 14 Similarly , imaging studies in non-human primates have shown significant recovery of DAT in animals exposed to METH 12-15 month after treatment. 15 Our human positron emission tomography (PET) study showed increased DAT after protracted (12-17 months) abstinence. 16 However, one nonhuman primate study documented striatal DA reductions still evident after 4 years post-METH treatment. 2 Both preclinical and clinical data provide evidence that METH is toxic to DA cells, but that some of the damage may recover with detoxification. However, all of the clinical studies in METH users are based on findings showing decreases of DA terminals (transporters). In this study we used PET and [ 11 C]raclopride to evaluate changes in extracellular DA in the striatum, which allowed direct assessment of the function of DA cells. PET with [ 11 C]raclopride has been used to study the involvement of DA in drug reward and addiction in the human brain. 17 This includes studies that investigate the relationships between the ability of various drugs to modulate DA and their reinforcing effects, both in non-dependent and drug-dependent individuals. [18] [19] [20] Using [ 11 C]raclopride, these studies have shown that stimulant drugs (i.e., methylphenidate (MPH) and amphetamine) increase DA in striatum in the human brain, and that these responses are attenuated in drug-addicted subjects. 21 In this study, PET imaging was performed after placebo (PL) and after oral MPH (60 mg). The METH abusers were initially tested within 6 months of last METH use and then followed for 9 months to assess whether striatal DA function in METH predicted abstinence at the end of this time period.
Subjects and methods

Subjects
The Institutional Review Boards at the Stony Brook University/Brookhaven National Laboratory, at Harbor-University of California-Los Angeles (HU-CLA) Medical Center and at the Portland Veterans Administration Medical Center (PVAMC) approved the protocol. Written informed consent was obtained after the experimental procedure was explained to the subjects. METH abusers (3 female and 13 male, 39.2 ± 4.9 years old) were recruited from HUCLA and PVAMC. METH was the subjects' primary drug of abuse via the smoked or intravenous routes, with a frequency of use at least five times/week and 0.5 g per day. Subjects that met a minimum 12-month history of METH abuse, DSM IV diagnosis for METH dependence and a minimum 2-week period of detoxification and desired to stop using METH were recruited for the study. The control group (2 female and 13 male, 37.2±4.3 years old) was chosen to match the age range of the METH group. Exclusion criteria for both groups were as follows: present or past history of neurological or DSM IV Axis I psychiatric disease (apart from METH dependence), past or present history of affective disorder or attention deficit disorder/attention deficit hyperactivity disorder , abuse or dependence of drugs other than METH (excluding nicotine), medical illness that can affect brain function, past or present history of cardiovascular disease or high blood pressure, scores on the Hamilton Depression Scale > 15, which may indicate clinical depression. Urine-screening tests for psychoactive drugs were performed to corroborate the lack of drug use.
Study design
Each subject was tested with two [ 11 C]raclopride scans (once after PL and once after 60 mg of oral MPH, which was be given an hour before [ 11 C]raclopride) to measure D2R availability and DA cell function. To avoid the carryover effects of MPH on subsequent scans, the [ 11 C]raclopride PET scan was done first after PL administration, and 2 h later after MPH administration. Blood samples were obtained to measure plasma MPH concentration before and at 30 and 60 min after MPH. The plasma concentration of MPH was analyzed at Dr Thomas Cooper's laboratory (Nathan Kline Institute, New York, USA). In addition, cardiovascular response (continuously recording vital signs and electrocardiogram) and self-report rating of drug effects (high, anxiety, restlessness, alertness and drug effect) to pharmacological doses of MPH were obtained before and at every 5 min after PL and MPH administration.
After the scan visits, the METH abusers were followed up in outpatient treatment facilities with random urine-screening tests for psychoactive drugs for the 9 months that followed their PET scan study. All enrollees attended the same substance abuse, daytreatment program weekly. The program consists of an intensive outpatient drug rehabilitation program that includes group and individual therapy and educational group sessions. The program includes early recovery skills and relapse-prevention techniques. Family counseling is also available. Anger management and domestic violence awareness and prevention programs are also available at the center for up to 52 weekly sessions. The subjects received behavioral and psychological treatments. The subjects did not receive any medical treatments during the rehabilitation process.
PET scanning
The PET scans were carried out on an HR þ Siemens tomograph (Malvern, PA, USA) using the 3-D acquisition mode. An external chinstrap device was used in addition to the individual head holder to minimize head motion during the scan. After a transmission image obtained for attenuation correction, scans were started immediately after injection of 5-10 mCi of [ 11 C]raclopride and were carried out for a total of 60 min. The following scanning sequences were used: 15 Â 1 min; 3 Â 5 min; and 2 Â 15 min. Each study included a measurement of the plasma clearance of total radioactivity and the measurement of the fraction of labeled tracer in plasma at selected times.
Image analysis
Both manual-drawn preselected regions of interest and statistical parametric mapping (SPM) analyses were used. The regions of interest in dorsal striatum (caudate, putamen), ventral striatum and cerebellum were outlined by superimposing boundaries from a neuroanatomical atlas using a template. 22 Briefly, the regions of interest were initially outlined on the individual's summed baseline [ 11 C]raclopride image (images obtained between 15 and 60 min), and were then projected into the dynamic [ 11 C]raclopride images to generate time-activity curves for the striatal regions (caudate, putamen and ventral striatum) and cerebellum. These time-activity curves for tissue concentration, along with the time-activity curves for unchanged tracer in plasma were used to calculate [ 11 C]raclopride's transfer constant from plasma to brain (K1) and the total tissue distribution volume (V T ). V T corresponds to the equilibrium measurement of the ratio of tissue concentration to plasma concentration in striatum and cerebellum using a graphical analysis technique for reversible systems. 23 The ratio of V T in striatum to that of V T in cerebellum corresponds to BP ND þ 1, where BP ND is the in vivo binding potential (non-displaceable). BP ND is proportional to the number available binding sites B avail /K d . The response to drug administration (with PL or with MPH) was quantied as the difference in B max /K d with respect to the baseline, PL condition.
Data analysis
Differences in BP ND , between conditions, were tested using a repeated measures analysis of variance model with two conditions (PL and MPH) and two groups (METH abuser and control), and post-hoc t-tests were then used to determine for which conditions the effects differed from the baseline condition. Plasma MPH concentration after oral administration were compared between the groups using Students' t-test. The effects of the MPH on the cardiovascular responses and behavioral self-reports were tested by comparing the scores obtained before the drug administration (PL and MPH) and the averaged scores obtained between 70 and 100 min after oral administration using a repeated measures analysis of variance. Pearson's product-moment correlations were used to assess the relationship between the MPHinduced changes in BP ND and the behavioral effects of the MPH. Using these statistics, we also tested whether clinical indices as cigarette smoking, years of METH use, amount of METH use and days of last METH use affected PL-or MPH-induced DA release in the abusers and as a function of abstinence versus relapse.
D2R image template
A spatial normalization template matching the average D2R image contrast in the brain was developed using V T images from 34 healthy control subjects. These parametric images were obtained from [ 11 C]raclopride PET scans, collected with the same scanning sequence used for the present study. All images were carefully inspected to ensure wholebrain coverage and exclude images with potential artifacts. A 12-parameter affine transformation with 16 nonlinear iterations was used to register the images to the PD.mnc Montreal Neurological Institute (MNI) template provided with the SPM2 package. The dimensions of bounding box of the output volumes were 90:90, 126:90 and 72:108 along x, y and z, respectively, and the voxel size was 2 Â 2 Â 2 mm 3 . Bilinear interpolation was used for reslicing. The average normalized and smoothed image (full width at half maximum = 8 mm) was computed to obtain the D2R image template in the MNI stereotactic space.
SPM analysis
Differences in D2R availability between MPH and PL in the METH abusers and in the controls, as well as between first visit and second visit were also tested on the voxel-level using the software package for SPM. Before the analysis, each subject's V T image was converted to the Analyze format, mapped onto the MNI stereotactic space using the custom D2R image template and the 12-parameter affine transformation in SPM2 with a 2 Â 2 Â 2 mm 3 voxel size, smoothed via a Gaussian kernel with FWHM of 8 mm and rescaled to the V T in cerebellum (V T ratio images). The V T ratio images were included into a repeated measures analysis of variance model with two conditions (PL and MPH) and two groups (METH abuser and control) for the group analyses in SPM2. Corrections for multiple comparisons were performed via the random field theory, an approach that is less conservative than the traditional Bonferroni method. Imaging voxels that were significantly different (Pp0.005, minimum cluster size = 100 voxels) between conditions were identified. The statistical significance of condition Â group interactions effects in the striatum were corrected for multiple comparisons using small volume corrections with a 10-mm diameter spherical volume in SPM. Only regions with corrected P-values p0.05 at the cluster-level were considered significantly. The MNI coordinates of the significant clusters were transformed to the Talairach space using a best-fit transform that minimizes bias associated with reference frame and scaling. 24 The brain regions were labeled according to the Talairach daemon 25 and a query range of 5-mm. We further checked the labels of the hubs using the Automated Anatomical Labeling atlas 26 and the Brodmann atlas, which is included in the MRIcron software (http:// www.nitrc.org/projects/mricron).
Results
The METH abusers differed from the controls in that they had lesser years of education (12.7 ± 1.6 vs 14.3±8.1 years, P < 0.001) and there was a greater proportion of cigarette smokers (16 METH abusers vs 4 controls, P < 0.001) and heavier cigarette smoking. Four METH abusers had moderate alcohol use and none of the controls use alcohol more than once per week. The METH abusers had a history of 13.1 ± 7.2 years METH use and 1.2±1.0 g per day.
After PL administration, 16 METH abusers had lower D2R availability in caudate (2.5 ± 0.2) than in controls (2.8±0.3, P < 0.04), Table 1 . Both METH abusers and controls reported greater ratings of drug effect ( þ 1.5 ± 1.7, P < 0.003; þ 2.3 ± 2.8, P < 0.007) and alertness ( þ 2.0±2.0, P < 0.001; þ 1.2±1.7, P < 0.02) after MPH than after PL administration, but the magnitude of these effects did not differ between groups. The controls, but not the METH abusers, reported greater ratings of 'high' ( þ 1.6±2.5, P < 0.03) after MPH. None of the groups reported neither increased anxiety nor restlessness after MPH. MPH administration increased pulse rate (METH abusers: þ 28.5 ± 28.1%, P < 0.001; control: 19.8 ± 16.8%, P < 0.0004) and diastolic pressure (METH abusers: þ 6.3±10.7%, P < 0.03; subjects: þ 7.8±12.1%, P < 0.03) in both groups and increased systolic pressure in the METH abusers ( þ 8.5 ± 6.5%, P < 0.0001), but not in the controls ( þ 3.8 ± 9.2%, not significant). However, the self-report ratings and cardiovascular changes after MPH were not significantly different between the groups. The plasma MPH concentrations at 30 and at 60 min were similar for the METH abusers (5.9 ± 6.1 ng ml À1 , 19.1 ± 6.2 ng ml À1 ) and the controls (8 ± 11.5 ng ml À1 , 21.8±8.9 ng ml À1 ).
After MPH administration, both METH abusers (caudate: À4 ± 7.3%, P < 0.04; putamen: À5.5 ± 8.3%, P < 0.01; ventral striatum: À4.1±14%, P < 0.06) and controls had decreased D2R availability (caudate: À6.4 ± 9.2%, P < 0.002; putamen: À10.5 ± 10%, P < 0.001; ventral striatum: À9.5 ± 13.5%, P < 0.007; Table 1 ), presumably reflecting DA increases. Comparison for groups' interaction effects was only significant for MPH-induced DA in left putamen (P < 0.05). The MP-induced decreases in left putamen in METH abusers were significantly smaller than in controls. There was no association between PL or MPH-induced DA release with clinical variables as cigarette smoking, years of METH use, amount of METH use and days of last METH use in the METH abusers. The plasma MPH levels were not associated with MPH-induced DA increases neither in METH abusers nor controls. SPM analysis, using a correction for small volume and multiple comparisons (P < 0.005), showed significantly decreased D2R availability in striatum after MPH in both controls and in METH abusers. The METH abusers had less decrement in putamen than in controls (coordinates in the MNI frame of reference: x = 38, y = À12, z = 6 mm; cluster volume = 482 voxels (2-mm isotropic); statistical significance: Z-score = 2.5; P < 0.036, false discovery rate-corrected for multiple comparisons using a small volume correction (10-mm spherical volume), Figure 1 ). There were no significant correlations between MPH-induced changes in BP ND and the behavioral effects of MPH.
Six METH abusers (two female and four male) relapsed after the PET scan visit. Four of these subjects had positive drug screens during the course of the study and two of the subjects were lost to follow-up, but the center was given informal feedback that the subjects had relapsed. There were no demographic (age, education) or clinical differences (years of METH, alcohol, tobacco use, amount of METH, alcohol, tobacco use and days of last METH use) between the six METH abusers who relapsed and those who did not. There were also no differences in self-report ratings and cardiovascular response to MPH administration between those who relapsed and those who did not.
The six METH abusers who relapsed showed no D2R availability changes after MPH (caudate: À0.7 ± 11%, not significant; putamen: À0.5 ± 10%, not significant), whereas in 10 METH abusers who did not relapse, MPH induced significant reduction in D2R availability (caudate: À6.6 ± 5%, P < 0.002; putamen: À8.5±5.6%, P < 0.001, Table 2 ). Post-hoc analysis showed that METH abusers who relapsed had significant lower D2R availability in caudate (P < 0.014) and putamen (P < 0.015) at baseline and less DA release after MPH in putamen (treatment Â diagnosis, P < 0.037) ( Figure 2 ). The amount of METH used by the six relapsed subjects did neither correlate with baseline D2R availability nor correlate with MPH-induced DA changes. The 10 METH abusers who remained abstinent showed a trend for lower baseline D2R availability (P < 0.07) and less MPH-induced DA release (treatment Â diagnosis, P < 0.07) in caudate than in the controls.
Discussion
The results show that METH abusers had lower baseline D2R availability (PL condition) in the caudate during early withdrawal, which replicates our previous findings in a different population of METH abusers. 27 Animal studies have implicated DA D2 receptors (D2R) located on striatal cells postsynaptic to the DA terminals in METH-induced toxicity. 28, 29 Imaging studies have also shown that long-term METH abuse leads to extensive neuronal damage in the human brain, which is associated with persistent cognitive impairment. 4 The subjects in this study received 60 mg MPH orally (0.75-1 mg kg À1 ) and showed the expected increases in extracellular DA concentration secondary to MPH-induced DAT blockade. The DA increases were not correlated with self-ratings of 'high', which is consistent with our previous studies showing that MPH-induced DA increases are only associated with the 'high' after intravenous, but not after oral administration. 22 The difference between the intravenous and oral administration of MPH, with respect to their reinforcing effects, most likely reflects the fact that the intravenous route leads to DA changes that are much faster than those observed after oral administration. Thus, the failure of oral MPH to induce a 'high' is likely because of slower pharmacokinetics (slower brain uptake). This is because the speed with which drugs of abuse enter the brain is a key parameter that affects their reinforcing effects; the faster their brain uptake the more intense their reinforcing effects. 30 The METH users showed lesser DA increases with MPH administration at early withdrawal than the controls. As DA increases induced by MPH are dependent on DA release (a function of DA cell firing), it is likely that the difference may reflect decreased dopaminergic cell activity in the METH abusers. While evaluating the results of PET studies based on the competition of [ 11 C]raclopride by endogenous DA, it is critical to remember that the results merely reflect the fraction of D2R that is vacant and thus capable of binding the tracer. As a consequence, any reduction in D2R measured with this technique could reflect either decreases in levels of D2R and/or increases in DA release (competing for binding with [ 11 C]raclopride for the D2R availability) in striatum (including nucleus accumbens). The increases in DA release could include pre-existing DA that was present before MPH administration or a combination of pre-existing DA plus DA that is released following MPH administration. If the presynaptic neuron in a METH abuser releases smaller amounts of DA (but fires at the same rate), the same observation would be seen. Other potential reasons for MPH-induced reductions in [ 11 C]raclopride binding were decreased DA affinity for the D2R or decreased efficacy of MPH to prevent DA reuptake. However, the fact that the METH abusers and other drug-addicted subjects (i.e., cocaine and alcohol) show blunted reductions in specific binding (indicative of decrease DA release) when administered MPH indicates that these individuals had both a reduction in the levels of D2R as well as a decrease in DA release in striatum. 20, 31 Each deficiency would contribute to the overall decreased sensitivity in drugaddicted subjects to natural reinforcers.
In this study, the METH abusers who showed greater DA increases after MPH administration during early withdrawal stayed sober and returned for the follow-up visit. In contrast, the METH users who showed no increases in DA after MPH during early withdrawal relapsed. A similar association was recently reported by a study in cocaine abusers that showed lower baseline striatal D2R availability and MPH-induced DA increases in cocaine abusers who relapsed versus those who did not. 32 Moreover in a previous study, these same investigators had shown a negative correlation between the increases in DA induced by amphetamine administration and their choice of cocaine over money; the lower the increases in DA, the more likely they were to select cocaine over a monetary reinforcer. 33 As the study also reported reduced DA increases in cocaine abusers when compared with controls, this could indicate that drug-addicted subjects with the most severe decreases in brain dopaminergic activity are the ones more likely to choose drugs over other reinforcers (such as money). Therefore, the failure of DAdepleted METH users to stay sober could occur because these individuals have a greater deficit in their ability to shift their reward-directed behavior to natural reinforcers. In this study, we found the METH users who relapsed had a blunted DA response to oral MPH in the dorsal striatum (caudate and putamen). During the development of drug addiction, drugseeking behavior progresses from seeking the rewarding effects of drugs to being triggered and maintained by drug-associated cues and stressful environments. 34 Prolonged drug seeking in vulnerable individuals results in habitual compulsive drug-using behavior 35, 36 and in increased DA release in dorsal striatum triggered by conditioned drug-cues. 36 In human cocaine abusers, increases in DA elicited by cocaine-cues in the dorsal striatum, are associated with the degree of drug craving and addiction severity. 37, 38 The dorsal striatum is also a major site that appears to be involved in relapse after prolonged abstinence from cocaine self-administration. 39 Greater deficits in dorsal striatal DA transmission in METH abusers might promote habitual drug use and a loss in the ability to stay sober.
Limitations for this study are the relatively small sample sizes, and even though we found group differences between relapse and control groups, we cannot ascribe a direct relationship between D2R availability and the prediction of relapse. Prospective studies in a larger number of METH abusers are needed to determine the sensitivity of striatal DA measures in predicting relapse versus abstinence. In this study, we excluded METH abusers with any history of an axis I disorder other than METH dependence, which limits the generalization of our findings, as comorbidity in METH abusers is high. Also, most of the METH abusers were cigarette smokers and continued to smoke throughout the study, which might have confounded the comparisons with controls, most of whom were non-smokers. 
Conclusion
The results revealed lower baseline striatal D2R availability and DA release in METH abusers than in controls, which replicates our previous studies. We also show that METH abusers, with better DA function during the early withdrawal period, were more likely to stay sober at follow-up than those with low striatal DA function. This coupled with similar findings in cocaine abusers, 32 suggest that poor DA function may be a biomarker that predicts a greater likelihood for relapse and a greater addiction severity. Thus, early detection of the extent of DA dysfunction may be helpful in predicting clinical outcomes.
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